17.1 Indications for Transfusion

17.1 Indications for Transfusion

Quick Answer: Transfuse for symptoms and inadequate oxygen delivery or hemostasis, not a single laboratory number. A common restrictive red-cell threshold is 7 g/dL in hospitalized, hemodynamically stable adults (TRICC; AABB guidance) and 8 g/dL in many orthopedic and cardiac-surgery guidelines. Those are guidelines, not ASCP official cutoffs and not a law that forbids transfusion at 7.2 or mandates it at 6.9. Prophylactic platelets are typically given at 10 × 10^9/L in a stable, nonbleeding, hypoproliferative patient; raise the bar for procedures, active bleeding, or CNS risk. Plasma treats coagulopathy with bleeding or an invasive procedure, not volume. Cryoprecipitate treats hypofibrinogenemia. Massive transfusion is defined by rate and volume of blood loss and is managed with balanced ratios, not red cells alone.

This is June 9, 2026 outline V.A. Chapter 4 told you what is in the bag. Chapter 11 told you why oxygen delivery fails. This section is when a unit is indicated. If a stem asks threshold, trigger, not indicated, plasma-for-volume, or massive-transfusion definition, answer it here. Manufacturing clocks, CMV labels, and washing stay in Chapters 4 and 17.2–17.4.

Transfuse the physiology, not the number

A hemoglobin, platelet count, or INR is a snapshot. The real question is whether the patient has inadequate oxygen-carrying capacity, inadequate primary hemostasis, or inadequate coagulation factors that a licensed component can fix.

Oxygen delivery is cardiac output × arterial oxygen content. A euvolemic, hemodynamically stable adult at 7.1 g/dL who is sitting up talking may not need a unit. The same number in a bleeding trauma patient, a patient with acute coronary ischemia and ongoing chest pain, or a neonate with congenital heart disease is a different physiology problem. Symptoms that support red-cell transfusion include unexplained tachycardia, hypotension not explained by volume alone, ischemic ECG changes, rising lactate, or documented end-organ ischemia. Asymptomatic iron deficiency at 9 g/dL needs iron, not red cells. Chronic anemia is often euvolemic; the patient has adapted. Acute hemorrhage is not euvolemic; hematocrit can still look almost normal until dilution occurs.

Do not invent an ASCP official hemoglobin, platelet count, or INR. The exam tests the restrictive versus liberal concept and the named trial and guideline numbers as common practice. They are not Board-owned statutes.

Restrictive red-cell thresholds — guideline, not law

The TRICC trial (Hébert et al., NEJM 1999) randomized critically ill euvolemic adults to a restrictive strategy (transfuse at 7 g/dL, maintain 7–9) versus a liberal strategy (transfuse at 10 g/dL, maintain 10–12). Restrictive transfusion was not inferior and was better in younger, less severely ill patients. That trial is why 7 g/dL appears on every blood-bank exam.

AABB clinical practice guidelines endorse a restrictive threshold of 7 g/dL for most hospitalized, hemodynamically stable adults, including many ICU patients, and a threshold of 8 g/dL for patients undergoing orthopedic or cardiac surgery and, in many summaries, for those with preexisting cardiovascular disease. TRICS III (cardiac surgery), FOCUS (hip-fracture), and related trials support managing those higher-risk surgical groups restrictively near 8 g/dL rather than a historical 10 g/dL.

Teach these as guidelines:

• They apply to hemodynamically stable, hospitalized patients.
• They do not replace clinical judgment in active hemorrhage, hemorrhagic shock, symptomatic anemia, or acute coronary syndrome with ischemia.
• They are not pediatric-specific law. Children are often dosed 10–15 mL/kg after a decision to transfuse has already been made.
• They are not never transfuse above 7. A bleeding patient at 8.5 g/dL can be an indicated transfusion.

A single-unit strategy in a stable adult is part of the same philosophy: give one unit, reassess hemoglobin and symptoms, then decide. Do not automatically issue two units because everyone gets two.

Platelet indications — prophylactic 10, then raise the bar

Hypoproliferative thrombocytopenia (chemotherapy, aplastic anemia, marrow failure) is the classic setting for prophylactic platelet transfusion. The TOPPS trial and AABB guidance support a trigger of 10 × 10^9/L in a stable, nonbleeding adult. That number is a guideline trigger, not a Board statute and not a reason to withhold platelets from a bleeding patient at 18 × 10^9/L.

Raise the threshold when risk is higher. Common practice and guideline ranges — again, not ASCP official unpublished cutoffs:

• Active bleeding: often treat toward ≥ 50 × 10^9/L
• Most invasive procedures and lumbar puncture: commonly ≥ 50 × 10^9/L
• Neurosurgery, intracranial hemorrhage, or posterior-chamber ocular surgery: commonly ≥ 100 × 10^9/L
• ITP, TTP, HIT, and some consumptive disorders: platelets are not first-line and can be harmful (TTP especially — 17.3)

Fever, sepsis, DIC, splenomegaly, and amphotericin make a 10 × 10^9/L count less safe; some services use 20 × 10^9/L prophylactically in those settings. Do not treat a count of 80 × 10^9/L in a stable, nonbleeding patient because platelets are sitting on the rotator.

Plasma is not volume

Plasma (FFP, PF24, thawed plasma) replaces soluble coagulation factors. The indication is coagulopathy plus bleeding or an imminent invasive procedure, not an isolated INR of 1.4 in a nonbleeding patient and not volume expansion. Crystalloid or colloid treats volume when oxygen-carrying capacity and coagulation are intact.

A commonly cited laboratory context is a significantly prolonged PT/INR or aPTT (many protocols use INR > 1.5–1.7) with bleeding or a procedure that will bleed. Mild INR elevation from warfarin is often better treated with vitamin K and, when urgent, 4-factor PCC rather than plasma (17.3). Plasma is also the replacement fluid for TTP plasma exchange — that is a disease-specific indication, not a low-factor snapshot.

Typical adult dose is about 10–20 mL/kg (roughly 3–6 units) if the goal is to raise factor levels. One unit will not correct a coagulopathy. Plasma does not contain a platelet dose and is a poor fibrinogen concentrate compared with cryoprecipitate.

Cryoprecipitate — fibrinogen first

Cryoprecipitate is indicated for hypofibrinogenemia or dysfibrinogenemia with bleeding or a procedure, for Factor XIII deficiency when a licensed concentrate is not used, and historically for hemophilia A or von Willebrand disease when factor concentrates are unavailable. In 2026 practice, factor concentrates and virally inactivated fibrinogen are preferred for inherited deficiencies; cryo remains the common acquired-hypofibrinogenemia product in U.S. trauma and obstetric hemorrhage.

A commonly used treatment threshold is fibrinogen < 100–150 mg/dL, with a bleeding target often 150–200 mg/dL (higher, sometimes ≥ 200 mg/dL, in obstetric hemorrhage protocols). Those are practice targets, not ASCP official numbers. Cryo is not a plasma volume expander and is not a TTP ADAMTS13 dose.

Massive transfusion — rate, then balance

Massive transfusion is defined by volume and speed, not by a magic hemoglobin. Classic definitions include replacement of one blood volume in 24 hours (about 10 red-cell units in an adult), ≥ 10 units in 24 hours, or ≥ 4 units in 1 hour with ongoing need. Some services use loss of 50% blood volume in 3 hours or an ABC score to activate a protocol before the 10th unit arrives. Do not memorize one unpublished ASCP official definition; know that the concept is life-threatening hemorrhage requiring a protocol, not a single leftover unit.

Once massive transfusion is underway, damage-control resuscitation uses balanced ratios of plasma, platelets, and red cells rather than crystalloid and packed cells alone. The PROPPR trial compared 1:1:1 versus 1:1:2 (plasma : platelets : red cells). The 1:1:1 group had better hemostasis and fewer deaths from exsanguination at 24 hours, with similar 24-hour and 30-day all-cause mortality. Many adult MTP protocols therefore issue in 1:1:1 packs (for example 6 RBC : 6 plasma : 1 apheresis platelet). Low-titer group O whole blood is an alternative balanced product in trauma (17.2).

Adjuncts belong in the protocol: tranexamic acid early in trauma and postpartum hemorrhage, calcium replacement (citrate binds ionized calcium), warming, and fibrinogen when the clot is weak. MTP is not keep giving O-negative red cells and check a CBC tomorrow.

Worked scenario. A hemodynamically stable 68-year-old on the ward has hemoglobin 7.3 g/dL, heart rate 78, and no chest pain. Restrictive guidance says a unit is not automatically required at 7.3. The same patient in the PACU after hip fracture with hemoglobin 7.6 g/dL and orthostatic hypotension is in the 8 g/dL orthopedic / symptomatic conversation. A third patient arrives in trauma with unmeasurable blood pressure and a hemoglobin of 9.1 g/dL — activate MTP; do not wait for 7.

Exam traps. The number is a guideline, not a law. TRICC/AABB 7 g/dL is the stable-adult default; 8 g/dL appears in cardiac, ortho, and CVD summaries. Platelets: 10 × 10^9/L prophylactic. Plasma is not volume. Cryo is fibrinogen. Massive transfusion is rate + balanced ratio, not red cells alone.